Tumor engraftment followed by mAb therapy targeting tumor antigens represents a gold standard for assessing the efficiency of mAbs to eliminate tumor cells. Mouse models have demonstrated that receptors for the Fc portion of IgG (FcγRs) are critical determinants of mAb therapeutic efficacy, but the FcγR-expressing cell populations responsible remain elusive. Here we show that neutrophils are responsible for mAb-induced therapy of both subcutaneous syngeneic melanoma and human breast cancer xenografts. mAb-induced tumor reduction was abolished in neutropenic mice, could be restored in FcγR-deficient hosts upon transfer of FcγR + neutrophils or upon human FcγRIIA/CD32A transgenic expression. Finally, conditional knockout mice unable to perform FcγR-mediated activation and phagocytosis specifically in neutrophils were resistant to mAb-induced therapy. Our work suggests that neutrophils are necessary and sufficient for mAb-induced therapy of subcutaneous tumors, and represent a new and critical focal point for optimizing mAb-induced immunotherapies that will impact on human cancer treatment.
INTRODUCTION
Murine tumor models are the main preclinical tools used to screen and optimize mAbs for potential anti-tumor mAb-mediated therapy in the clinic. These models consist of implanting syngeneic mouse cancer cells into immunocompetent mice or xenogeneic human cancer cells into immunodeficient mice, followed by intravenous injections of potential therapeutic mAbs. Most anti-tumor therapeutic mAbs target an antigen expressed by the tumor and were designed to limit tumor growth by inducing cellular apoptosis or growth arrest 1 . Several reports, however, indicate that the immune effector response is highly relevant to the efficacy of therapeutic mAbs in vivo in mouse models 2 . Importantly, mice deficient for all activating FcγRs (FcRγ -/mice) are not protected from the growth of gp75-expressing syngeneic melanoma or of HER2-expressing breast cancer xenografts following anti-gp75 (TA99) or anti-HER2 (Trastuzumab) mAb treatment, respectively 3, 4 . Furthermore, polymorphisms in FcγR-encoding genes in patients (e.g.
FcγRIIIA/CD16A and FcγRIIA/CD32A) have been reported to impact mAb therapeutic efficacy 5,6 .
However, the FcγR-expressing cell populations responsible for the mAb-induced therapeutic activities on tumors have not been formally identified. In vitro, FcγR + NK cells and various FcγR + myeloid cells 7-10 can all kill mAb-opsonized tumor cells. In vivo, however, it is unclear which of these cells types plays the dominant role in mAb induced anti-tumor effects.
For personal use only. on March 31, 2017. by guest www.bloodjournal.org From
RESULTS & DISCUSSION
We used tumor cell lines expressing the enhanced firefly luciferase (luc2) to allow accurate, non-invasive, assessment of tumor burden over time using bioluminescence acquisition 11, 12 . A subcutaneous injection of luc2-expressing syngeneic gp75 + B16-F10 (B16-luc2) melanoma into wild-type mice led to a localized tumor development ( Fig.1A, Fig.S1A ).
Recurrent injections of anti-gp75 mAb TA99 reduced bioluminescence to background level as early as 24-48h following the first injection and prevented reoccurrence of detectable tumors in wild type mice ( Fig.1A, Fig.S1A ) but not in FcRγ -/mice ( Fig.S1B ), as reported 3 . Anti-gp75 mAb injections starting on day 0 or day 2, but not on day 7, post-tumor engraftment efficiently reduced the tumor burden ( Fig.S1C ). The protective effect in this mAb therapy model can therefore be monitored using bioluminescence before appearance of detectable tumor masses, and mimics the clinical efficacy of anti-tumor mAbs on small or residual tumors and their relative inefficiency on larger tumors 13 . The potential contribution of FcγR + cell populations 14 to anti-tumor mAb immunotherapy could therefore be investigated in the first days following mAb therapy. NK cells did not detectably contribute to anti-gp75 immunotherapy, as demonstrated by NK cell deficiency 15 (Fig.1B) or depletion ( Fig.S1D) . Similarly, monocytes/macrophages were not involved, as demonstrated by monocyte/macrophage depletion (Fig.1C, Fig.S2A ) or by their inhibition by gadolinium (data not shown). This latter result was unexpected in view of the critical role of macrophages reported in the depletion of B cells after anti-CD20 therapy 10,16 , but may rely on the tissue localization of the target cells, i.e. subcutaneous versus circulating, respectively. Finally, a role for mast cells, basophils or eosinophils could be ruled out . Mouse protocols were approved by the Animal Care and Use Committees of Paris, France. As demonstrated previously 3 , FcRγ -/mice failed to respond to anti-gp75 treatment following tumor transfer ( Fig.S1B ). Although bone marrow cell transfers from wt mice into FcRγ -/-RAG -/mice restored anti-gp75 immunotherapy ( Fig.1D ), transfers on days 0 and 1 were not sufficient to protect mice from tumor outgrowth ( Fig.S3A ). This result suggested that a shortlived bone marrow cell population may mediate the protection. Among short-lived bone marrow cells, neutrophils have been reported to have a lifespan of 12.5 hours in mice 17 . Importantly, anti-Gr1-induced depletion of neutrophils abolished anti-gp75 immunotherapy (Fig.1E, Fig.S3B -C).
Although myeloid-derived suppressor cells (MDSCs) also express Gr1, it is unlikely that the depletion of MDSCs is contributing to the loss of the therapeutic activity of TA99 in this model, as B16 cells have been reported not to induce MDSCs 18 . Because antibody-induced cell depletion might also affect other cell populations in this setting, we used a mouse model of neutropenia 19 , induced by the absence of transcriptional repressor growth factor independence-1 (Gfi1) 20 ( Fig.S3D ). Whereas tumor growth was identical in Gfi1-deficient and Gfi1-sufficient (Gfi1 +/-) mice, anti-gp75 immunotherapy was abolished in the absence of Gfi1 (Fig.1F, Fig.S3E ). Taken together, our results suggest that Gr1 + cells, deficient in Gfi1 -/mice, i.e. neutrophils, are mandatory for anti-tumor mAb therapeutic efficacy.
We next extended our observations to the HER2/neu + human breast cancer cell line BT474-M1 that has been used to assess the therapeutic activity of Trastuzumab 4 . A subcutaneous injection of a luc2-expressing BT474 cells (BT474-luc2; Fig.S4A Fig.2A ). Using suboptimal doses of anti-Gr1 resulted in a partial reduction of neutrophil numbers that correlated with a partial loss of the efficacy of Trastuzumab on tumor growth ( Fig.S4E ). Of note, BT474 cells, like B16 cells, do not produce GM-CSF and therefore do not induce MDSCs 18 . Moreover, Gfi1-deficient nude mice were resistant to Trastuzumab treatment ( Fig.2B) . These data indicate that neutrophils are also mandatory for the anti-tumor effect of Trastuzumab on HER2-expressing breast cancer xenografts. To further demonstrate a role for myeloid cells, but not for NK cells in this model we used transgenic mice expressing the human FcγRIIA/CD32A gene in neutrophils and other myeloid cells, but not NK cells 21, 22 . Expression of this transgene restored Trastuzumab efficacy in FcRγ -/nude mice (Fig.2C, Fig.S4F ).
We next investigated if neutrophils were sufficient to overcome a host environment resistant to mAb therapy. Daily transfers of purified neutrophils from wt mice, but not from FcRγ -/mice, into recipient FcRγ -/mice restored anti-gp75 immunotherapy (Fig.2D, Fig.S5A ).
Thus activating IgG receptors are only required on neutrophils to allow mAb-mediated therapy.
Neutrophils may thus be responsible by themselves for mAb-induced tumor reduction. Purified human blood neutrophils ( Fig.S5B ) could, indeed, induce the killing of BT474-luc2 cells only in the presence of Trastuzumab ( Fig.2E ) suggesting a requirement for physical interaction between neutrophils and opsonized target cells in vivo 7 . Histological analysis revealed foci of Gr1 + cells with a neutrophil morphology in the tumor outer rim only after anti-gp75 mAb injection ( Fig.2F ), whereas similar numbers of CD3 + , CD45R + or F4/80 + cells were present in either presence or absence of therapy ( Fig.S5C-D) . These foci contained Ly6G + cells, indicating that these were neutrophils ( Fig.2G ).
Finally, we investigated by which mechanism neutrophils contribute to these models of anti-cancer immunotherapy. Neither a deficiency in cytokines (TNF-α or Interferon-γ), in Our work provides a mechanistic basis for the observed reduction in tumor burden following anti-tumor mAb injection in both syngeneic and xenograft mouse models of cancer immunotherapy. The selective requirement and the sufficiency of neutrophils to mediate IgGinduced anti-tumor activities we reveal may also extend to emerging models of IgA mAb-antitumor therapy, which have been proposed to rely on complement and on IgA receptor (CD89)expressing neutrophils 28 . Although significant differences between mouse and human neutrophils including the activating IgG receptors they express have been reported 14,17 , the principles that have emerged from these mouse studies are likely to apply to human immunotherapy protocols.
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